SERBEST ECZACILARIN PROTON POMPASI İNHİBİTÖRLERİ HAKKINDAKİ BİLGİ, TUTUM VE UYGULAMALARI

Öz

Amaç: Bu çalışma, serbest eczacıların proton pompası inhibitörleri (PPİ'ler) hakkındaki bilgi, tutum ve uygulamalarını değerlendirmeyi amaçlamıştır. Gereç ve Yöntem: Çalışma, kesitsel bir çevrimiçi anket çalışmasıydı. 1 Kasım 2022-15 Nisan 2023 tarihleri arasında Türkiye'deki serbest eczacılarla yapılmıştı. Anket soruları bir önceki çalışmanın revize edilmesiyle oluşturulmuş olup 32 sorudan oluşmaktadır. Bunlardan 4’ü demografik bilgiler, 16’sı bilgi, 6’sı tutum ve 6’sı uygulamalara ilişkindir. Sonuç ve Tartışma: Eczacıların büyük çoğunluğu (%97.6) pantoprazol, omeprazol vb. ilaçların PPİ olduğunu, eczacıların büyük çoğunluğu (%84.5) PPİ'lerin inaktif ön ilaç olduğunu biliyordu. Eczacıların %63.1’i omeprazolün bireysel değişkenliğe sahip olduğunu doğru yanıtlamıştı. Eczacıların büyük çoğunluğu (%93.5) PPİ'lerin Türkiye'de gereğinden fazla kullanıldığına inanmaktaydı. Eczacıların %86.3’ü aşırı PPİ tüketiminin maliyet artışına ve advers ilaç reaksiyonlarına yol açtığına inanmaktaydı. 46 eczacı (%27.38) son 1 yılda PPİ kullandığını beyan etti. Pantoprazol (%15.5) ve lansoprazol (%7.7) sırasıyla en sık kullanılan PPİ idi. Çalışmamıza göre eczacıların PPİ’lerle ilgili bilgi, tutum ve uygulamaları genel olarak iyi olmakla birlikte bazı bilgi eksiklikleri de vardı. Bu nedenle eczacıların kendilerini güncellemeleri ve meslek içi sürekli eğitimlerle desteklenmeleri gerekmektedir.

Anahtar Kelimeler

• Bilgi
• proton pompa inhibitörleri
• serbest eczacılar
• tutum
• uygulamalar

Destekleyen Kurum

YOK

Proje Numarası

YOK

Teşekkür

YOK

KNOWLEDGE, ATTITUDES AND PRACTICES OF COMMUNITY PHARMACISTS ABOUT PROTON PUMP INHIBITORS

Öz

Objective: This study aimed to evaluate the knowledge, attitudes, and practices of community pharmacists about proton pump inhibitors (PPIs). Material and Method: The study was a cross-sectional online survey study It was conducted with community pharmacists in Türkiye between 1 November 2022 and 15 April 2023. The survey questions were created by revising the previous study and consisted of 32 questions. Of these, 4 were about demographic information, 16 were about knowledge, 6 were about attitude, and 6 were about practices. Result and Discussion: The vast majority of pharmacists who participated into the study (97.6%) knew that drugs such as pantoprazole, omeprazole, etc. were PPIs, and a majority of pharmacists (84.5%) knew that PPIs were inactive pro-drugs. 63.1% of the pharmacists answered correctly that omeprazole had the most individual variability. The vast majority (93.5%) of pharmacists believed that PPIs were overused in Türkiye. 86.3% of pharmacists believed that excessive consumption of PPIs resulted in increased costs and adverse drug reactions. 46 pharmacists (27.38%) declared that they have used PPIs in the last 1 year. Pantoprazole (15.5%) and lansoprazole (7.7%) were the most commonly used PPIs, respectively. According to our study, although pharmacists' knowledge, attitudes, and practices about PPIs were generally good, there were also some deficiencies in their knowledge. Therefore, pharmacists need to update themselves and be supported by interdisciplinary continuous educations.

Anahtar Kelimeler

• Attitudes
• community pharmacists
• knowledge
• practices
• proton pump inhibitors

Proje Numarası

YOK

Kaynakça

1. 1. Horn, J. (2000). The proton-pump inhibitors: Similarities and differences. Clinical Therapeutics, 22(3), 266-280. [CrossRef]
2. 2. Strand, D.S., Kim, D., Peura, D.A. (2017). 25 years of proton pump inhibitors: A comprehensive review. Gut and Liver, 11(1), 27. [CrossRef]
3. 3. Castellana, C., Pecere, S., Furnari, M., Telese, A., Matteo, M.V., Haidry, R., Eusebi, L.H. (2021). Side effects of long-term use of proton pump inhibitors: Practical considerations. Polish Archives of Internal Medicine, 131(6), 541-549. [CrossRef]
4. 4. Schubert, M.L. (2020). Proton pump inhibitors: Misconceptions and proper prescribing practice. Current Opinion in Gastroenterology, 36(6), 493-500. [CrossRef]
5. 5. Schoenfeld, A.J., Grady, D. (2016). Adverse effects associated with proton pump inhibitors. JAMA Internal Medicine, 176(2), 172-174. [CrossRef]
6. 6. Tandun, R., Bubbar, C., Tejani, A.M. (2019). Who has the guts to deprescribe proton pump inhibitors? A pharmacist‐led intervention in a long‐term care facility setting. Aging Medicine, 2(2), 112-117. [CrossRef]
7. 7. Wahking, R.A., Steele, R.L., Hanners, R.E., Lockwood, S.M., Davis, K.W. (2018). Outcomes from a pharmacist-led proton pump inhibitor stewardship program at a single institution. Hospital Pharmacy, 53(1), 59-67. [CrossRef]
8. 8. Odenthal, D.R., Philbrick, A.M., Harris, I.M. (2020). Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic. Journal of the American Pharmacists Association, 60(1), 100-104. [CrossRef]

9. 9. Hong, Y., Ye, Z., Gao, Z., Rao, Y. (2020). Continuous improvement on the rationality of prophylactic injectable PPIs usage by a clinical pharmacist-led guidance team at a Chinese tertiary teaching hospital. Journal of International Medical Research, 48(10), 0300060520954729. [CrossRef]
10. 10. Dumlu, H.I., Sancar, M., Ozdemir, A., Okuyan, B. (2022). Impact of a clinical pharmacist-led stewardship program for the appropriate use of acid suppression therapy in older hospitalized patients: A non-randomized controlled study. International Journal of Clinical Pharmacy, 44(4), 914-921. [CrossRef]
11. 11. Okumura, L.M., Rotta, I., Correr, C.J. (2014). Assessment of pharmacist-led patient counseling in randomized controlled trials: A systematic review. International Journal of Clinical Pharmacy, 36, 882-891. [CrossRef]
12. 12. Boardman, H.F., Heeley, G. (2015). The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. International Journal of Clinical Pharmacy, 37, 709-716. [CrossRef]
13. 13. Luo, H., Fan, Q., Bian, T., Li, X., Chen, K., Zhang, Q., Li, Y. (2019). Awareness, attitude and behavior regarding proton pump inhibitor among medical staff in the Southwest of China. BMC Health Services Research, 19, 1-9. [CrossRef]
14. 14. Türk Eczacıları Birliği. Hastaya, kamuya, eczacıya ilaçtır. (2020). Available at: https://dergi.tebeczane.net/public_html/kitaplar/bilgilendirmekitapcigi/html5/index.html?&lo. Accessed date: 01.06.2022.
15. 15. Çelebi, F., Çalıkuşu, M., Özçelikay, G. (2022). The role of community pharmacists in increasing patients' drug compliance. Fabad Journal of Pharmaceutical Sciences, 47(3), 339-346. [CrossRef]
16. 16. Çalıkuşu, M., Güneş, G., Özçelikay, G. (2021). Covid-19 Pandemisinin toplum eczacılığı hizmetlerine etkileri. Journal of Faculty of Pharmacy of Ankara University, 45(2), 194-211. [CrossRef]
17. 17. Raosoft Inc. (2004) RaoSoft® sample size calculator. Available at: http://www.raosoft.com/samplesize.html. Accessed date: 01.06.2022.
18. 18. Hamurtekin, E., Boşnak, A.S., Azarbad, A., Moghaddamshahabi, R., Hamurtekin, Y., Naser, R.B. (2023). Knowledge, attitude, and practices regarding proton pump inhibitors among community pharmacists and pharmacy students. Nigerian Journal of Clinical Practice, 26(2). [CrossRef]
19. 19. Asdaq, S.M.B., Albasha, M., Almutairi, A., Alyabisi, R., Almuhaisni, A., Faqihi, R., Alhomrani, M. (2021). Use of proton pump inhibitors: An exploration of awareness, attitude and behavior of health care professionals of Riyadh, Saudi Arabia. Saudi Pharmaceutical Journal, 29(7), 713-718. [CrossRef]
20. 20. Mahmoudi, L., Mohammadi, R., Niknam, R. (2019). Economic impact of pharmacist interventions on correction of stress-related mucosal damage prophylaxis practice. Clinico Economics and Outcomes Research, 111-116. [CrossRef]
21. 21. Forgacs, I., Loganayagam, A. (2008). Overprescribing proton pump inhibitors. British Medical Journal, 336(7634), 2-3. [CrossRef]
22. 22. Savarino, V., Marabotto, E., Zentilin, P., Furnari, M., Bodini, G., De Maria, C., Savarino, E. (2018). Proton pump inhibitors: Use and misuse in the clinical setting. Expert Review of Clinical Pharmacology, 11(11), 1123-1134. [CrossRef]
23. 23. Özdemir, B., Ön, K.B., Altıner, E. (2022). Uşak Eğitim ve Araştırma Hastanesi’ne başvuran hastalarda proton pompa inhibitörü kullanım yaygınlığının incelenmesi. Ege Tıp Bilimleri Dergisi, 5(1), 11-15. [CrossRef]
24. 24. Michelon, H., Delahaye, A., Fellous, L., Davido, B., Dinh, A., Le Quintrec, J.L., Herr, M. (2019). Proton pump inhibitors: Why this gap between guidelines and prescribing practices in geriatrics? European Journal of Clinical Pharmacology, 75, 1327-1329. [CrossRef]
25. 25. Abraham, N.S. (2012). Proton pump inhibitors: Potential adverse effects. Current Opinion in Gastroenterology, 28(6), 615-620. [CrossRef]
26. 26. Luo, H., Fan, Q., Xiao, S., Chen, K. (2017). Impact of clinical pharmacist interventions on inappropriate prophylactic acid suppressant use in hepatobiliary surgical patients undergoing elective operations. PLoS One, 12(10), e0186302. [CrossRef]
27. 27. Luo, H., Fan, Q., Xiao, S., Chen, K. (2018). Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital. BMC Health Services Research, 18(1), 1-10. [CrossRef]
28. 28. Bilgener, E. (2018). Türkiye’de 2006-2011 yıllarında proton pompası inhibitörleri tüketiminin bütçeye etkisi. Journal of Faculty of Pharmacy of Ankara University, 42(2), 23-31. [CrossRef]
29. 29. Horn, J. (2000). The proton-pump inhibitors: Similarities and differences. Clinical Therapeutics, 22(3), 266-280. [CrossRef]